Skip to main content

Primary Immune Deficiency Disorders

4
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
3 programs
2
1
GammaplexPhase 41 trial
GammaplexPhase 31 trial
SubgamPhase 31 trial
Active Trials
NCT01963143Completed48Est. May 2016
NCT01884311Completed38Est. May 2017
NCT01289847Completed25Est. Apr 2014
ADMA Biologics
ADMA BiologicsNJ - Ramsey
1 program
1
Immune Globulin Intravenous (Human)Phase 3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiocorpGammaplex
BiocorpSubgam
BiocorpGammaplex

Clinical Trials (3)

Total enrollment: 111 patients across 3 trials

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

Start: Mar 2011Est. completion: Apr 201425 patients
Phase 4Completed

Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases

Start: Aug 2015Est. completion: May 201738 patients
Phase 3Completed

Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases

Start: Feb 2014Est. completion: May 201648 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.